维泊妥珠单抗联合RCHP用于治疗初诊弥漫性大B细胞淋巴瘤的成本-效用OA

Objective To evaluate the economics of polatuzumab vedotin combination with rituximab,cyclophosphamide,doxorubicin,and prednisone(PolaRCHP)in patients with previously untreated diffuse large B-cell lymphoma(DLBCL).Methods From the perspective of Chinese health system,a three-state Markov model was constructed based on the PLOARIX trail to analyze the cost-utility of PolaRCHP and rituximab combined with cyclophosphamide,Doxorubicin,vincristine and prednesone(RCHOP).The simulation time of the model is lifetime,the cycle is 3 weeks,and the utility and cost are discounted at an annual discount rate of 5%.Total cost,health benefit and incremental cost-effectiveness ratio(ICER)were measured.And the robustness of the model was examined by single factor sensitivity analysis and probabilistic sensitivity analysis.Results Cost-utility analysis results showed that PolaRCHP resulted in an increase of 2.70 QALYs in previously untreated patients with diffuse large B-cell lymphoma compared to RCHOP.The total cost increased by 210 134.00 yuan,and the ICER was 77 745.26 yuan/QALY,which was lower than the WTP threshold of 1 times per capita GDP(85 698 yuan/QALY),indicating that the PolaRCHP scheme was more economical.The sensitivity analysis results show that as each variable fluctuates within the range,ICER is always smaller than 3 times per capita GDP.Under the threshold of 1 times China's per capita GDP,the probability of PolaRCHP being economical is 96.45%.Conclusion Under the WTP threshold of 1 times China's per capita GDP,compared with RCHOP,PolaRCHP is more economical for the treatment of previously untreated diffuse large B-cell lymphoma in Chinese health system.